Cell Cycle and Cervical Carcinoma retinoblastoma protein. Proc Natl Acad Sci USA 1994; 91:2945-9. 45. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblas- toma protein with human D cyclins. Cell 1993;73:499- 511. 46. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expres- sion in cervical cancer and cervical intraepithelial neoplasia. Pathol Int 1998;48:580-5. 47. Amortegui AJ, Meyer MP, Elborne VL, Amin RM. p53, retinoblastoma gene product, and cyclin protein ex- pression in human papillomavirus virus DNA-positive cervical intraepithelial neoplasia and invasive cancer. Mod Pathol 1995;8:907-12. 48. Choo KB, Chong KY. Absence of mutation in the p53 and the retinoblastoma susceptibility genes in primary cervical carcinomas. Virology 1993;193:1042-6. 49. Chetty R, Bramdev A, Aguirre-Arteta A, Pegoraro RJ, Sataar N. Relation between retinoblastoma and p53 proteins in human papilloma viruses 16/18 positive and negative cancers of the uterine cervix. J Clin Pathol 1997;50:413-6. 50. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991;88:5523-7. 51. Fiedler M, Muller-Holzner E, Viertler HP, Widschwendter A, Laich A, Pfister G, et al. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb- levels in cervical biopsies. FASEB J 2004;18:1120-2. 52. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74. 53. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-indepen- dent pathway. Cancer Res 1994;54:3391-5. 54. Lie AK, Skarsvag S, Skomedal H, Haugen OA, Holm R. Expression of p53, MDM2, and p21 proteins in high- grade cervical intraepithelial neoplasia and relationship to human papillomavirus infection. Int J Gynecol Pathol 1999;18:5-11. 55. Kim YT, Cho NH, Park SW, Kim JW. Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma. Gynecol Oncol 1998;71:38-45. 56. Huang LW, Chou YY, Chao SL, Chen TJ, Lee TT. p53 and p21 expression in precancerous lesions and carci- nomas of the uterine cervix: overexpression of p53 pre- dicts poor disease outcome. Gynecol Oncol 2001;83:348- 54. 57. Van de Putte G, Holm R, Lie AK, Trope CG, Kristensen GB. Corrigendum to “Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis”. Gynecol Oncol 2004;92:730. 58. Giannoudis A, Herrington CS. Differential expression of p53 and p21 in low grade cervical squamous intrae- pithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer 2000;89: 1300-7. 59. Werness BA, Wang HQ, Chance J, Goldstein DJ. p53- independent expression of p21WAF1/Cip1 in preinva- sive and invasive squamous neoplasms of the uterine cervix. Mod Pathol 1997;10:578-84. 60. Lu X, Toki T, Konishi I, Nikaido T, Fujii S. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer 1998;82:2409-17. 61. Graflund M, Sorbe B, Karlsson M. Immunohistochemi- cal expression of p53, bcl-2, and p21(WAF1/CIP1) in early cervical carcinoma: correlation with clinical outcome. Int J Gynecol Cancer 2002;12:290-8. 62. Cheung TH, Lo KW, Yu MM, Yim SF, Poon CS, Chung TK, et al. Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett 2001;172: 93-8. 63. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. Multiple functions of p27(KIP1) and its alterations in tumor cells: a review. J Cell Physiol 2000;183:18-27. 64. Shiozawa T, Shiohara S, Kanai M, Konishi I, Fujii S, Nikaido T. Expression of the cell cycle regulator p27 (KIP1) in normal squamous epithelium, cervical intrae- pithelial neoplasia, and invasive squamous cell carci- noma of the uterine cervix. Immunohistochemistry and functional aspects of p27(KIP1). Cancer 2001;92:3005-11. 65. Huang LW, Chao SL, Hwang JL, Chou YY. Down- regulation of p27 is associated with malignant trans- formation and aggressive phenotype of cervical neo- plasms. Gynecol Oncol 2002;85:524-8. 66. Goff BA, Sallin J, Garcia R, VanBlaricom A, Paley PJ, Muntz HG. Evaluation of p27 in preinvasive and inva- sive malignancies of the cervix. Gynecol Oncol 2003;88: 40-4. 67. Kim YT, Choi EK, Cho NH, Ko JH, Yang WI, Kim JW, et al. Expression of cyclin E and p27KIP1 in cervical carcinoma. Cancer Lett 2000;153:41-50. 68. Troncone G, Vetrani A, de Rosa G, Gerbasio D, Palombini L. Cyclin dependent kinase inhibitor p27KIP1 expression in normal and neoplastic cervical epithelium. J Clin Pathol 1999;52:880-7. 69. Sgambato A, Zannoni GF, Faraglia B, Camerini A, Tarquini E, Spada D, et al. Decreased expression of the CDK inhibitor p27KIP1 and increased oxidative DNA damage in the multistep process of cervical carcino- genesis. Gynecol Oncol 2004;92:776-83. 70. Dellas A, Schultheiss E, Leivas MR, Moch H, Torhorst J. Association of p27KIP1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervi- cal neoplasms. Anticancer Res 1998;18:3991-8. 71. Erlandsson F, Wahlby C, Ekholm-Reed S, Hellstrom AC, Bengtsson E, Zetterberg A. Abnormal expression pattern of cyclin E in tumour cells. Int J Cancer 2003; 104:369-75. 72. Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, et al. Expression of cyclins E1 and E2 during mouse Yonsei Med J Vol. 46, No. 5, 2005